top of page

Low-dose immune checkpoint inhibitor + immune cell therapy

MAKI CLINIC

About Opdivo

Opdivo, also known as an immune checkpoint inhibitor, is a new drug in recent years that can have an effect on non-small cell lung cancer that cannot be surgically removed or has progressed and relapsed. A monoclonal antibody-targeted drug improves human immunity and inhibits tumor growth by promoting T cell immune responses.

About Yervoy

Yervoy is also known as an immune checkpoint inhibitor. Inhibiting CTLA-4 signaling will also reduce the function of regulatory T cells and promote an overall increase in T cell reactivity, including anti-tumor immune responses, to achieve the effect of treating cancer. , a new type of immune checkpoint inhibitor

immune checkpoint inhibitors

Immune cells themselves have the ability to attack and eliminate foreign matter from the body. In the early stages, when there are fewer cancer cells, immune cells are usually able to eliminate cancer cells. However, if immune cells are overactivated, they may trigger an autoimmune reaction that attacks their own normal cells. Therefore, the surface of immune cells has some molecules that inhibit immune responses. These molecules are called immune checkpoints, and some cancer cells contain molecules that can inhibit the immune response. Molecules that act on immune checkpoints to prevent immune responses from occurring. Therefore, the role of immune checkpoint inhibitors is to block the function of these molecules and awaken the original ability of immune cells so that they can attack cancer cells. Immune checkpoint inhibitors have been shown to be effective against a variety of cancers, based on results from multiple clinical trials.

6377387325017367021274715.png

免疫檢查點抑制劑運作原理

low-dose immune checkpoint inhibitors

Recent clinical trials in India have shown that the use of ultra-low-dose immune checkpoint inhibitor Opdivo can significantly extend the survival of patients with advanced head and neck cancer. This dose is equivalent to only 6% of the usual dosage in the United States and Europe, greatly reducing the cost of treatment and particularly helping low- and middle-income countries. The study, which included 151 patients, showed that those who received standard treatment plus ultra-low-dose Opdivo had a survival rate of 43% after one year, compared with 16% of those who received standard treatment alone. This shows that ultra-low-dose Opdivo can not only improve survival rates, but also significantly reduce the cost of treatment, which is only 5% to 9% of the cost of full-dose treatment. This discovery has important implications for global access to cancer treatment and is expected to benefit more patients.

截圖 2024-06-03 16.02.43.png

※上述印度臨床試驗的論文發表於2022年。

Maki診所早在2015年左右就已經發現「Opdivo在低劑量下也能充分發揮療效」。

Side Effects Confirmed by Opdivo in Japan

  • Interstitial lung disease (pneumonia, lung infiltrates, lung injury, etc.)

  • Myasthenia gravis, myocarditis, myositis, rhabdomyolysis, or comorbidities of these conditions

  • Colitis, enteritis, severe diarrhea

  • type 1 diabetes

  • Severe blood disorders (immune thrombocytopenic purpura, hemolytic anemia, agranulocytosis, etc.)

  • Pulmonary insufficiency, liver dysfunction, hepatitis, sclerosing cholangitis

  • Thyroid dysfunction

  • pituitary dysfunction

  • nervous disorder

  • kidney dysfunction

  • adrenal dysfunction

  • encephalitis

  • severe skin disorder

  • venous thromboembolism

  • hemophagocytosis syndromegroup

  • tuberculosis

  • pancreatitis

 

For these side effects, corresponding management and treatment should be carried out according to the specific conditions of the patients. if inOpdivoAny discomfort or side effects during use should be reported to a doctor immediately for proper treatment and treatment.

Remarks: Taiwan has aboutOpdivoReferences for side effects

Yervoy adaptation symptoms

unresectable malignant melanoma

incurable or metastatic renal cell carcinoma

After chemotherapy,Unresectable colorectal cancer with MSI-High

Unresectable progressive, recurrent non-small cell lung cancer

Unresectable progressive,recurrent malignant pleural mesothelioma

Remarks: Taiwan has aboutYervoyReferences for Adaptive Symptoms

Immunocell Therapy

Immunotherapy using lymphocytes is a medically based cancer treatment method that was first reported at an academic conference in Japan in 1980. It has been reported to be effective not only for cancer treatment but also for preventing recurrence after surgery. In most cases, immunotherapy can be given even to patients who cannot undergo surgery or chemotherapy. In addition, it has been receiving attention as a mild cancer treatment method following surgical treatment, chemotherapy, and radiation therapy because of its milder side effects compared to other cancer treatments.

Immunocell therapy is a treatment method that extracts immune cells from the patient's blood, cultivates them, activates them, and returns them to the body to attack cancer through the enhanced autoimmune system. Because it uses the patient's blood components, there are almost no side effects. Maki Clinic commissioned the culture laboratory of Yokohama Tsurumine Hospital to cultivate and activate immune cells. It is a technically sophisticated medical institution that provides immune cell culture technology guidance to countries such as South Korea and China.

  • Activation of your own linpa ball transfer therapy (CAT therapy)

It is also called "CD3-LAK therapy" or "α/β T cell therapy." T cells are extracted from the blood, activated and cultured with CD3 antibodies and a cytokine called IL-2, and then returned to the body after being sufficiently strengthened. This is a treatment method that has been proven in a large number of cases and can be used by all patients.

  • NK Cell Therapy

NK cells are natural killer cells that have a strong attack power against cancer and are an immune cell therapy that is expected to achieve a high therapeutic effect. This treatment method uses high concentrations of IL-2, various antibodies, and special technologies to activate and proliferate NK cells in lymphocytes contained in peripheral blood, and then return them to the patient's body. On average, activated NK cells account for 65% of the total number (45% to 85%).

Clinic introduction

Comfortable and spacious clinic interior

PRPIC-20160427113719.jpg

Dean's introduction

inchou2_edited.jpg

Dr.

SAITOU  SAIJI

1991 Graduated as Chief of Nagasaki University School of Medicine ​

 

Served in

Hekinan Municipal Hospital

Aichi Prefectural Hospital ​

 

Association

Japanese Society of Internal Medicine

Japanese Society of Aesthetic Surgeons ​

Japan Anti-Aging Cosmetic Medical Society

 

2004 Maki clinic established

Clinic address

〒460-0011 22-22

Osu301, 4f, 3-chome-30-60 Osu, Naka Ward, Nagoya, Aichi 460-0011

If you have any questions, please feel free to contact us through any of the methods below.

Name: *

Mailbox: *

Telephone: *

message:

メッセージを报信しました

CONTACT US

TW contact only: +886-90-5563-717

JP For emergency contact: +81-80-4276-3930

 

​JP Tel / Fax:  +81-92 -984-3200

 

Mail: service@medicalsupporter.org

LINE@ ID: @medicalsupporter

 

LINE & WeChat & Skype: medicalsupporter

  • Facebook
  • Instagram
LINE@
medicalsupportrterjp.jpg
LINE
WeChat
bottom of page